Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 133-138

  Tsujimoto, Masayuki ^a   Higuchi, Keishi ^a   Shima, Daisuke ^a   Yokota, Hitoshi ^a   Furukubo, Taku ^b   Izumi, Satoshi ^b   Yamakawa, Tomoyuki ^b   Otagiri, Masaki ^c   Hirata, Sumio ^c   Takara, Kohji ^a   Nishiguchi, Kohshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 2C9; Losartan metabolism; Uraemic serum; Uraemic toxin

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 3 (3 CARBOXY 4 METHYL 5 PROPYL 2 FURYL)PROPIONIC ACID; ACETIC ACID; CRESOL; HIPPURIC ACID; INDICAN; INDOLEACETIC ACID; LOSARTAN; UNCLASSIFIED DRUG; UREMIC TOXIN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; LIVER MICROSOME; MAJOR CLINICAL STUDY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARYL HYDROCARBON HYDROXYLASES; CRESOLS; HUMANS; IMIDAZOLES; INDICAN; KIDNEY FAILURE, CHRONIC; LOSARTAN; MICROSOMES, LIVER; RENAL DIALYSIS; TETRAZOLES; UREMIA;

EID: 77949493617     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0015     Document Type: Article

References (21)

1. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074.
2. Sica DA et al. Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 2000; 38: 519-526.
3. Kearns GL, Young RA. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use. Clin Pharmacokinet 1994; 26: 169-189.
4. Tsujimoto M et al. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin. Ther Drug Monit 2008; 30: 576-582.
5. Hanada K et al. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol 2006; 103: 179-186.
6. Tsutsumi Y et al. Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2- furanpropanoic acid, on human serum albumin. Pharm Res 1999; 16: 916-923.
7. Nishikawa M et al. Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 2004; 19: 280-289.
8. Yamaoka K et al. A pharmacokinetic analysis program (multi. for microcomputer). J Pharmacobio-dyn 1981; 4: 879-885.
9. Liebich HM et al. Hippuric acid and 3-carboxy-4-methyl-5-propyl-2- furanpropionic acid in serum and urine. Analytical approaches and clinical relevance in kidney diseases. J Chromatogr 1990; 2: 615-627.
10. Sakai T et al. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. J Pharmacol Exp Ther 1996; 278: 786-792.
11. de Smet R et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998; 278: 1-21.
12. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003; 16: 45-50.
13. Dreisbach AW et al. Cytochrome P450 2C9 activity in endstage renal disease. Clin Pharmacol Ther 2003; 73: 475-477.
14. Nolin TD et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006; 17: 2363-2367.
15. Sun H et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004; 32: 1239-1246.
16. Brown HS et al. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for prediction of metabolic clearance. Drug Metab Dispos 2007; 35: 293-301.
17. Christ DD et al. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 1994; 268: 1199-1205.
18. Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995; 35: 515-520.
19. Leblond FA et al. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-1320.
20. Leblond F et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 326-332.
21. Leblond FA et al. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2002; 13: 1579-1585.